{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:01:33Z","timestamp":1785427293073,"version":"3.56.0"},"reference-count":34,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2022YFC2705003"],"award-info":[{"award-number":["2022YFC2705003"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141125"],"award-info":[{"award-number":["82141125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82141125"],"award-info":[{"award-number":["82141125"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["21Y31900302"],"award-info":[{"award-number":["21Y31900302"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"award":["21Y31900302"],"award-info":[{"award-number":["21Y31900302"]}],"id":[{"id":"https:\/\/ror.org\/03kt66j61","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Children\u2019s Hospital of Fudan University Clinical Postdoctoral Program of \u201cFuture Medical Scientists\u201d","award":["LCBSH00000002"],"award-info":[{"award-number":["LCBSH00000002"]}]},{"award":["LCBSH00000002"],"award-info":[{"award-number":["LCBSH00000002"]}],"id":[{"id":"https:\/\/ror.org\/05n13be63","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Febrile neutropenia (FN) is a major complication of chemotherapy in pediatric hematological malignancies. This study compared the efficacy and safety of prophylactic pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) versus daily short-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF). Methods: This single-center, open-label, randomized controlled trial was conducted at a tertiary children\u2019s hospital in China. Pediatric patients (&lt;18 years) with confirmed hematological malignancies (leukemia or lymphoma) were enrolled. A total of 138 chemotherapy cycles were randomized 2:1 to receive either a single dose of PEG-rhG-CSF (100 \u03bcg\/kg, n = 86 cycles) or daily short-acting rhG-CSF (5 \u03bcg\/kg\/day, n = 45 cycles) after chemotherapy. The primary endpoint was FN incidence. Secondary endpoints included neutropenia incidence, FN duration, time to neutrophil recovery, blood product transfusions, hospital stay, and costs. Safety was assessed by monitoring adverse events (AEs) graded according to NCI CTCAE version 4.03. Results: Baseline characteristics were comparable between groups. PEG-rhG-CSF significantly reduced the incidence of FN (59.3% vs. 77.7%, OR 0.42 (0.18\u20130.97), p = 0.046) compared to daily rhG-CSF. The median time to neutrophil recovery was 9.8 days (95% CI: 8.1\u201310.7) in the PEG-rhG-CSF group and 10.3 days (95% CI: 8.6\u201311.1) in the control group (p = 0.45). No significant differences were observed in FN duration, transfusions, hospital stay, or costs. Subgroup analyses showed PEG-rhG-CSF significantly reduced FN in non-Hodgkin lymphoma (57.4% vs. 83.3%, OR 0.27 (0.08\u20130.89), p = 0.032). A total of 12 AEs (9.9% overall, mainly bone pain) were observed, with no significant difference between groups and no infection-related deaths. Conclusions: In this single-center, open-label trial, prophylactic single-dose PEG-rhG-CSF was associated with a lower incidence of FN compared to daily short-acting rhG-CSF. Safety profiles appeared broadly similar, but the sample size was insufficient to detect rare differences.<\/jats:p>","DOI":"10.3390\/cancers18142214","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:55:32Z","timestamp":1783598132000},"page":"2214","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic PEG-rhG-CSF Reduces Febrile Neutropenia in Pediatric Hematological Malignancies Compared with Daily rhG-CSF"],"prefix":"10.3390","volume":"18","author":[{"given":"Xiao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, National Children\u2019s Medical Center, Children\u2019s Hospital of Fudan University, Shanghai 201102, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Children\u2019s Medical Center, Children\u2019s Hospital of Fudan University, Shanghai 201102, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Children\u2019s Medical Center, Children\u2019s Hospital of Fudan University, Shanghai 201102, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Children\u2019s Medical Center, Children\u2019s Hospital of Fudan University, Shanghai 201102, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Children\u2019s Medical Center, Children\u2019s Hospital of Fudan University, Shanghai 201102, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Children\u2019s Medical Center, Children\u2019s Hospital of Fudan University, Shanghai 201102, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Children\u2019s Medical Center, Children\u2019s Hospital of Fudan University, Shanghai 201102, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Children\u2019s Medical Center, Children\u2019s Hospital of Fudan University, Shanghai 201102, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11912-017-0578-5","article-title":"Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions","volume":"19","author":"Wang","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1200\/JCO.22.02224","article-title":"Guideline for the Management of Fever and Neutropenia in Pediatric Patients with Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update","volume":"41","author":"Lehrnbecher","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/jps.20024","article-title":"Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats","volume":"93","author":"Yang","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2172292","DOI":"10.1080\/16078454.2023.2172292","article-title":"Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: A systematic review and meta-analysis","volume":"28","author":"Zhu","year":"2023","journal-title":"Hematology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2009.25.8988","article-title":"Predicting adverse events in children with fever and chemotherapy-induced neutropenia: The prospective multicenter SPOG 2003 FN study","volume":"28","author":"Ammann","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/MPH.0b013e3181f6921a","article-title":"Risk factors associated with life-threatening infections in children with febrile neutropenia: A data mining approach","volume":"33","author":"Badiei","year":"2011","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.ejca.2009.06.003","article-title":"Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting","volume":"45","author":"Dommett","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jinf.2019.06.008","article-title":"Differential risk of severe infection in febrile neutropenia among children with blood cancer or solid tumor","volume":"79","author":"Delebarre","year":"2019","journal-title":"J. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1056\/NEJM199009273231304","article-title":"Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia","volume":"323","author":"Ohno","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","article-title":"Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy","volume":"29","author":"Green","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1182\/blood.V87.8.3143.bloodjournal8783143","article-title":"A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-M\u00fcnster Study Group","volume":"87","author":"Welte","year":"1996","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","article-title":"A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group","volume":"90","author":"Heil","year":"1997","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199706193362503","article-title":"Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia","volume":"336","author":"Pui","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0959-8049(98)00061-6","article-title":"An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma","volume":"34","author":"Michon","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/0091270006288731","article-title":"Pharmacokinetic\/pharmacodynamic modeling of pegfilgrastim in healthy subjects","volume":"46","author":"Roskos","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/CAD.0b013e3283610b5d","article-title":"Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: A multicenter, randomized, crossover phase 3 study","volume":"24","author":"Shi","year":"2013","journal-title":"Anticancer Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/annonc\/mdv174","article-title":"The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy","volume":"26","author":"Lyman","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"877","article-title":"Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma","volume":"15","author":"Mey","year":"2007","journal-title":"Support Care Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1634\/theoncologist.12-4-484","article-title":"Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use","volume":"12","author":"Ozer","year":"2007","journal-title":"Oncologist"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10428190500305802","article-title":"Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin\u2019s lymphoma","volume":"47","author":"Pro","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1078155217714859","article-title":"Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events","volume":"24","author":"Bond","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s12325-018-0798-6","article-title":"Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia","volume":"35","author":"Cornes","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2009.24.8872","article-title":"Phase II, randomized, open-label study of pegfilgrastim-supported VDC\/IE chemotherapy in pediatric sarcoma patients","volume":"28","author":"Spunt","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1200\/JCO.1996.14.3.901","article-title":"Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy","volume":"14","author":"Wexler","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.1158\/1078-0432.CCR-09-0761","article-title":"Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas","volume":"15","author":"Fox","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_30","first-page":"525","article-title":"Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: A systematic review","volume":"23","author":"Pfeil","year":"2015","journal-title":"Support Care Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20012","DOI":"10.1073\/pnas.1116110108","article-title":"Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age","volume":"108","author":"Pang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15374","DOI":"10.1038\/s41598-019-51982-4","article-title":"Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_33","first-page":"504","article-title":"Prophylactic recombinant human granulocyte\/granulocyte-macrophage colony-stimulating factor in children with hematologic malignancies after chemotherapy","volume":"37","author":"Fu","year":"2017","journal-title":"Tumor"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 Statement: Updated guideline for reporting randomised trials","volume":"388","author":"Hopewell","year":"2025","journal-title":"BMJ"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:32:48Z","timestamp":1784007168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":34,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142214"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142214","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}